Patents
Literature
2 results about "Hyperkalemia" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Hyperkalemia, also spelled hyperkalaemia, is an elevated level of potassium (K⁺) in the blood serum. Normal potassium levels are between 3.5 and 5.0 mmol/L (3.5 and 5.0 mEq/L) with levels above 5.5 mmol/L defined as hyperkalemia. Typically this results in no symptoms. Occasionally when severe it results in palpitations, muscle pain, muscle weakness, or numbness. An abnormal heart rate can occur which can result in cardiac arrest and death.
A traditional Chinese medicine composition for delaying the progression of kidney deficiency and blood stasis syndrome in diabetic nephropathy, its application and preparation method
PendingCN122075626Aeffective treatmentImprove pathological damageMetabolism disorderUrinary disorderDiabetic kidneyPlantago asiatica
This invention relates to a traditional Chinese medicine composition for delaying the progression of kidney deficiency and blood stasis syndrome in diabetic nephropathy, its application, and preparation method. The composition is made from Astragalus membranaceus, Salvia miltiorrhiza, Paeonia lactiflora, Anemarrhena asphodeloides, Phellodendron chinense, Cistanche deserticola, Scutellaria baicalensis, Euonymus alatus, Schisandra chinensis, raw oyster shell, Plantago asiatica, and Artemisia annua. It has the effects of nourishing the kidneys, clearing heat, eliminating toxins, and unblocking the meridians. This traditional Chinese medicine composition can effectively delay the decline in renal function in patients with massive proteinuria during the diabetic nephropathy stage, improve the clinical symptoms of patients with kidney deficiency and blood stasis syndrome, and improve their quality of life. Simultaneously, it has a low risk of hyperkalemia and gastrointestinal bleeding, and no significant damage to liver function has been observed, indicating high safety.
Owner:THE FIRST AFFILIATED HOSPITAL OF TIANJIN UNIV OF TRADITIONAL CHINESE MEDICINE
Pharmaceutical polymers for treating hyperkalemia and their preparation methods
This disclosure pertains to the field of medicinal chemistry and relates to pharmaceutical polymers for the treatment of hyperkalemia and methods for their preparation. Specifically, this document provides potassium-binding polymers prepared by polymerization of monomers and crosslinking agents, wherein the monomers are compounds of formula (V), and the crosslinking agents are compounds of formula (VI) and / or formula (VII), wherein the variables are as defined in this specification; this application relates to their use in the treatment or prevention of hyperkalemia.
Owner:WATERSTONE PHARMA (WUHAN) CO LTD